Background: Diagnosis of basal-like breast cancer (BLBC) remains a bottleneck to conducting effective clinical trials for this aggressive subtype. We postulated that elevated expression of Forkhead Box transcription factor C1 (FOXC1) is a simple and accurate diagnostic biomarker for BLBC.
article high rate of metastasis to the brain and/or lung within three to five years of initial presentation, and have poor overall survival (4-7). Standard chemotherapy is not effective against BLBC, which currently lacks personalized, targeted therapeutic options.
One of the major obstacles in developing effective therapeutic options for BLBC has been the inability to accurately identify this molecular subtype using standard histopathological techniques. Most clinical trials have utilized the triple-negative phenotype (TNP)-negative for the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)-to define BLBC. The fact that BLBC is not synonymous with triple-negative breast cancer has been established by several investigators (3, 8, 9) . Utilizing additional immunohistochemistry (IHC) markers (such as basal cytokeratins CK5/6, CK 14, CK17, and epidermal growth factor receptor [EGFR] ) to better define BLBC has proven to be superior to using only the TNP, but they still lack accuracy (2, 10, 11) . One glaring problem with current IHC protocols is their inability to diagnose the known occurrence of BLBC in ER+ and HER2+ tumors. In fact, 20% to 30% of BLBC tumors express ER and/or HER2 markers (Curtis and Parker datasets; Supplementary Figure 1 , available online) (12, 13) . Thus validation of a diagnostic test for the accurate identification of BLBC in the clinic remains a critical bottleneck in efforts directed to personalize therapy for BLBC (14, 15) . Such a test needs to preserve the accuracy of BLBC prediction observed with the gene expression microarray/ multimarker quantitative real-time polymerase chain reaction (qRT-PCR) PAM50 test (that can cost several thousand dollars), but enable performance in the end-user pathology laboratory at less than a tenth of the cost (13) . A single marker for identification of basal-like breast cancer would reduce technical errors involved in a multimarker test and be easily integrated into current pathology practice alongside the established ER and HER2 tests.
A functional transcriptomics approach originally led to the identification of Forkhead Box C1 (FOXC1) as a characteristic tissue level biomarker for BLBC (10, 16, 17) . Herein we validate the use of FOXC1 as a diagnostic and prognostic biomarker for BLBC, as compared with the PAM50 panel, to define this aggressive molecular subtype in large human microarray and qRT-PCR datasets (12, 13) . We report results of synchronous profiling of FOXC1 mRNA and protein expression in an independent cohort of matched human breast cancer samples (Table 1;  Supplementary Table 1 , available online). Our studies may lead to the development of a pragmatic, inexpensive molecular diagnostic test for BLBC with ready applicability for use in the clinic.
Methods

Immunohistochemistry of Formalin-Fixed ParaffinEmbedded Samples
Formalin-fixed paraffin-embedded (FFPE) blocks from 118 patients enriched for 'triple-negative' breast cancer were drawn from the archives of the Department of Pathology at Carle Foundation Hospital, Urbana, IL in accordance with the approval of the Carle Institutional Review Board (Table 1 
FFPE Sample Subtyping Analyses
Centroid data for each PAM50-defined molecular subtype described by Parker et al. (13) 
Statistical Analysis
Prognostic significance of FOXC1 in predicting disease-specific survival was examined in the Curtis et al. dataset (12) . Organ-specific metastasis-free survival was examined in the van de Vijver et al. dataset (24) . Kaplan-Meier plots were generated using Prism software (GraphPad Software, La Jolla, CA). Univariate and multivariate analyses were performed using Cox regression model (SAS software, SAS Institute Inc., Cary, NC). Assumptions of proportionality were tested by inspecting plots of log(-log(survival function)) vs log(survival time) under different predictor values, and by testing statistical significance of the interaction effects of predictors and log(survival time) (Supplementary Table 2 , available online). If the proportionality assumption was violated, the average effects of hazard ratios over time are provided (Table 2; Supplementary Table 3 , available online). For our final results, we did not need to rely on proportionality assumptions. Variables included in the multivariate analysis are age, tumor size, lymph node status, and either PAM50 or FOXC1-defined BLBC status ( Table 2 ). All tests were two-sided, and P values of less than .05 were considered statistically significant.
Results
Generation and Validation of FOXC1 Antibody for IHC
To improve IHC detection of the FOXC1 protein in human breast cancers, we generated a monoclonal mouse antibody against the FOXC1 N-terminal domain. The specificity of this antibody for detection of nuclear FOXC1 was confirmed using immunoblotting and immunofluorescence of MCF-7 breast cancer cells (which expressed low or undetectable FOXC1 levels) transfected with either vector control, Myc-tagged 
FOXC1 Protein Expression in FFPE Tissue Sections as Determined by IHC
This portion of the study was performed in accordance with STARD guidelines (See STARD diagrams in the Supplementary Materials, available online) (18, 19) . The patterns of IHC staining were scored by three pathologists individually. All three pathologists remained blinded with respect to laboratory (ER, PR, HER2, PAM50 molecular subtype) and clinical data (staging, etc.). Prior to first examination, the three pathologists met and agreed to perform initial scoring by overall intensity and percentage of positive cancer cells (FOXC1 staining is nuclear in location) in increments of 1 below 10%, and thereon in 'buckets' of 10%, leading to a scoring process based upon the established 'H' and Allred scoring guidelines for ER and PR (25) (26) (27) . A finalized modified Allred Score for the IHC assessment of FOXC1 positivity, using a 0 to 8 score, was developed by three pathologists (CRT, WYP, XL) who were blinded to the receptor profile and molecular subtype of the matched breast cancer samples (Supplementary Figure 3 , available online). The IHC staining results for FOXC1 compared with both CK 5/6 and EGFR for FFPE samples clustered by the PAM50 genes are shown in Figure 1A . Comparatively, FOXC1 protein is specific to basal-like tumors and not merely enriched in this subset.
FOXC1 Expression as a Predictor of Basal-Like Subtype
The molecular subtype of 96 FFPE samples enriched for triplenegative phenotype was determined using the PAM50 panel of genes. The molecular subtype prediction relative to ER/HER2 marker status is shown in Supplementary Table 1 (available  online) Because FOXC1 is included in the PAM50 panel, we repeated the above analysis in our cohort by first classifying tumors using PAM50 minus FOXC1. As expected for the removal of a single gene from the PAM50 analysis, only two designations were altered when FOXC1 was removed from the PAM50 subtyping (both from Basal-like to Luminal B subtype) (13, 22) . The AUCs for the IHC (AUC = 0.84) and qRT-PCR (AUC = 0.90) tests in the reassigned, FOXC1-excluded (PAM49) dataset are comparable with the values obtained from the full PAM50 assignments.
Based on the above data, if IHC testing alone was to be utilized for detection of FOXC1 expression in human FFPE breast cancer tissue using these protocols, the cutoff that maximizes the sum of sensitivity and specificity would be either 4 or 5 (Supplementary Figure 4A , available online). However, this approach has a lower sensitivity and/or specificity relative to the more-difficult-to-perform qRT-PCR test. To maximize the simplicity and short turnaround time of IHC and retain the performance of qRT-PCR, we examined a novel two-tier reflex strategy in which an initial IHC test would only require supplemental qRT-PCR for intermediate IHC FOXC1 scores; thus balancing ease of implementation with maximal test accuracy. FOXC1 IHC scores of 0-3 were considered to be negative, 6-8 were considered to be positive, and 4-5 were considered to be equivocal for FOXC1 expression. Samples scored 4-5 would automatically "reflex" to the FOXC1-based qRT-PCR assay as the more quantitatively accurate test. Using this model we obtained superior sensitivity and specificity of 0.84 and 0.94, respectively (AUC = 0.88) (Supplementary Figure 4B , available online). This single marker, two-tier testing strategy is comparable with other BLBC definitions such as TNP (sensitivity = 0.93, specificity = 0.79) and core-basal phenotype (sensitivity = 0.91, specificity = 0.85). However, unlike both TNP and core-basal phenotype, FOXC1 is capable of identifying basallike tumors in both ER+ and HER2+ tumors. FOXC1 expression is capable of identifying basal-like tumors independent of ER or HER2 expression status with high sensitivity and specificity (Figure 4) .
Validation of FOXC1 as a Prognostic Biomarker
With the goal of validating the earlier reported prognostic significance of FOXC1 in breast cancer by accurately detecting the BLBC molecular subtype, we examined the 1992-sample Curtis et al. dataset with respect to disease-specific survival (DSS) and the 295-sample van de Vijver et al. dataset with respect to distant metastasis-free survival (DMFS) (10, 12, 16, 24) . In univariate analysis, DSS was statistically significantly worse for patients identified as having either PAM50-defined BLBC ( Figure 5A ) or FOXC1-defined BLBC (P < .001) ( Figure 5B). The hazard ratio (HR) for disease-specific survival in patients having FOXC1-defined BLBC was 1.71 (95% CI = 1.31 to 2.23, P < .001), comparable with PAM50 assay-defined BLBC (HR = 1.74, 95% CI = 1.40 to 2.17, P < .001) ( Table 2 ). In multivariate analysis, FOXC1 expression was an independent prognostic indicator of DSS after adjusting for clinical/pathologic variables such as age, tumor size, and lymph node status (top 10th decile cutoff used in this validation dataset based on predetermined cutoff value from earlier training datasets, HR = 1.55 95% CI = 1.17 to 2.06, P = .003), and again was comparable with PAM50 basal-like designation (HR = 1.56, 95% CI = 1.23 to 1.98, P = .001) ( Table 2) (10, 16) . Furthermore, the FOXC1-defined Basal-like designation allowed prognostic stratification of lymph node-negative breast cancer patients similar to the PAM50 basal-like designation (P = .002 and .007, respectively) in the Curtis dataset ( Figure 5, C and D) . Using multivariate analysis FOXC1-defined Basal-like designation was confirmed to be an independent prognostic indicator even in this lymph node-negative subset of patients (Supplementary Table 3 , available online).
Elevated FOXC1 expression was also found to be positively associated with brain (P = .04) and lung (P = .01) metastasis in the van de Vijver dataset, (Supplementary Figure 5 , available online), further validating this predictive association reported earlier in another independent dataset (10, 24) . This correlation was stronger than the PAM50 basal-like association with brain metastasis (P = .31) and comparable with that for lung metastasis (P = .01) (Supplementary Figure 5 , available online). While both FOXC1 and PAM50 basal-like designations exhibited a negative correlative trend with bone metastasis, neither correlation was statistically significant (P = .61 and .23 for PAM50 and FOXC1, respectively) (Supplementary Figure 5, available online) . The ability to accurately identify BLBC tumors with a single gene biomarker holds promise of greatly increasing the clinical application of BLBC status in assessing patient outcomes. 
Discussion
Sequencing of the human genome has improved our understanding of the molecular underpinnings of human disease and accelerated development of tailored personalized therapeutics for complex diseases, including cancer. While several tissue level cancer biomarkers are reported in the literature every year, few survive validation to warrant utilization in clinical management. This attrition may be because of the fact that while strong associations are often initially derived between putative biomarker expression and disease status, candidate markers often fail to have any meaningful and disease-relevant function in clinical laboratory and therapeutic practice.
Using a transcriptomics-driven approach, we initially reported that mRNA overexpression of FOXC1 was a tissuelevel biomarker of BLBC and was superior to surrogate biomarker panels (10) . We subsequently went on to suggest that FOXC1 protein overexpression also appeared to be a highly characteristic feature of BLBC, albeit in an independent cohort of human breast cancer tissue samples (16) . FOXC1 mRNA and protein expression levels were demonstrated to be specific for basal-like breast cancer tissue and/or cell lines (on microarray analysis and immunoblotting). Finally, and most importantly, FOXC1 was demonstrated to be of critical and central importance in orchestrating the aggressive biology and metastatic potential of BLBC (17, 28) . As such FOXC1 represents a potential therapeutic target and/ or surrogate predictive marker of therapeutic efficacy in BLBC. However, with respect to its diagnostic potential, the accuracy of FOXC1 protein expression as measured by IHC had never been compared with the academic gold standard definition of BLBC, namely multimarker gene expression on a microarray platform (Intrinsic Gene List) or multimarker gene expression on a qRT-PCR platform (PAM50). Absent such a study, the cost-effective diagnosis of BLBC based on IHC FOXC1 expression could not be proposed.
In the present study we used a large, publicly available microarray dataset to validate the prognostic importance of FOXC1 expression in breast cancer reported previously using other datasets, thereby confirming its accuracy in predicting BLBC-associated poor prognosis (10, 12, 16) . Importantly, in both the prior and current datasets, the prognostic predictive ability of FOXC1 expression was also confirmed using multivariate analysis (Supplementary  Table 3 , available online) in the lymph node-negative subset of patients, who might otherwise be expected to have had more favorable outcomes. Prognostic significance of FOXC1 with regard to predicting organ-specific metastases and survival was also validated in an independent dataset. We further demonstrated the proof-of-concept of an in vitro molecular diagnostic test, the FOXC1-based two-tier assay, for the accurate detection and diagnosis of BLBC comparable with the qRT-PCR-based PAM50 assay. This diagnostic test is based on the IHC detection of the FOXC1 transcription factor in FFPE human breast cancer tissues using an epitope-specific monoclonal antibody developed specifically for that purpose. The test has the benefit of having a second tier single-gene qRT-PCR test available to resolve the diagnostic dilemma that arises when equivocal results are obtained on IHC alone.
It has been assumed that BLBC is found only within triplenegative breast cancers and is not found in those tumors that express ER and HER2. Contrary to such an assumption and in agreement with prior reports in the literature, we identified BLBC in non-triple negative breast cancer samples, both in microarray and qRT-PCR datasets as well as FFPE profiled samples (Figure 4 ; Supplementary Table 1 , available online), suggesting that all breast samples, as opposed to only triplenegative breast cancer samples, should be evaluated for harboring a BLBC molecular subtype (29) . Assessment of FOXC1 expression meets this need. Other proposed methods of identifying BLBC, including TNP status or core-basal staining (TNP with positive staining for EGFR and/or CK 5/6), by definition will not identify BLBC in ER+ or HER2+ tumors.
The main limitation of the current study is its retrospective design. Also the conclusions cannot be generalized, as all patients were treated either in the United States or Europe at different time points. As the distribution of clinical characteristics might be different in patients from other areas (even within the United States and Europe), the current study should be considered to suffer from biases inherent to such a study design. Our results do however suggest that they merit further largescale retrospective and ultimately prospective independent validation.
In summary, based on the above results, we propose that a highly sensitive and specific, two-tier testing strategy for FOXC1 expression may be the diagnostic assay of choice for BLBC. This would be akin to the current concept of determining HER2 status in the clinic, which uses a combination of IHC and fluorescent in situ hybridization assays, the latter to aid definitive diagnosis of HER2 expression status in those cases that have equivocal results rendered on initial IHC for HER2. The two-tier FOXC1-based molecular diagnostic assay for BLBC merits further large scale validation ideally in the context of a multi-institutional retrospective study, prior to undertaking prospective validation at independent centers. Such a study is currently underway. expression can identify PAM50-defined BLBC with high sensitvity and specificity in all subgroups defined by estrogen receptor and human epidermal growth factor receptor 2 IHC expression in both a microarray dataset (Curtis et al. [12] ) and quantitative real-time polymerase chain reaction dataset (Parker et al. [13] ). Cutoff levels of FOXC1 for BLBC prediction are optimized for each marker subgroup. Cutoff values are given for expression levels of the entire dataset and not for each individual subgroup. ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2. All P values are two-sided. BLBC = basal-like breast cancer; DSS = disease-specific survival.
